BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cofrogliptin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cofrogliptin\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07122102-426@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Cofrogliptin: Phase na readout est. (NCT07122102)
DESCRIPTION:Cofrogliptin\, phase na\, Type 2 Diabetes.\nStudy: A Multicente
 r\, Randomized\, Open-Label\, Parallel-Controlled Clinical Study Comparing
  the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Pa
 tients With Type 2 Diabetes\nEstimated primary completion: 30 June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cofrogliptin#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07122102
URL:https://assetmemo.bio/drug/cofrogliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07460336-426@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cofrogliptin: Phase na readout est. (NCT07460336)
DESCRIPTION:Cofrogliptin\, phase na.\nStudy: Effects of Cofrogliptin on Bet
 a-Cell Function in LADA Patients\nEstimated primary completion: 31 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/cofrogliptin#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0746
 0336
URL:https://assetmemo.bio/drug/cofrogliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
